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BACKGROUND: Endovascular treatment with mechanical thrombectomy (MT) 
is beneficial for patients with acute stroke suffering a large-vessel occlusion, 
although treatment efficacy is highly time-dependent. We hypothesized that 
interhospital transfer to endovascular-capable centers would result in treatment 
delays and worse clinical outcomes compared with direct presentation.
METHODS: STRATIS (Systematic Evaluation of Patients Treated With 
Neurothrombectomy Devices for Acute Ischemic Stroke) was a prospective, 
multicenter, observational, single-arm study of real-world MT for acute stroke 
because of anterior-circulation large-vessel occlusion performed at 55 sites over 
2 years, including 1000 patients with severe stroke and treated within 8 hours. 
Patients underwent MT with or without intravenous tissue plasminogen activator 
and were admitted to endovascular-capable centers via either interhospital transfer 
or direct presentation. The primary clinical outcome was functional independence 
(modified Rankin Score 0–2) at 90 days. We assessed (1) real-world time metrics of 
stroke care delivery, (2) outcome differences between direct and transfer patients 
undergoing MT, and (3) the potential impact of local hospital bypass.
RESULTS: A total of 984 patients were analyzed. Median onset-to-revascularization 
time was 202.0 minutes for direct versus 311.5 minutes for transfer patients 
(P<0.001). Clinical outcomes were better in the direct group, with 60.0% 
(299/498) achieving functional independence compared with 52.2% (213/408) in 
the transfer group (odds ratio, 1.38; 95% confidence interval, 1.06–1.79; P=0.02). 
Likewise, excellent outcome (modified Rankin Score 0–1) was achieved in 47.4% 
(236/498) of direct patients versus 38.0% (155/408) of transfer patients (odds 
ratio, 1.47; 95% confidence interval, 1.13–1.92; P=0.005). Mortality did not differ 
between the 2 groups (15.1% for direct, 13.7% for transfer; P=0.55). Intravenous 
tissue plasminogen activator did not impact outcomes. Hypothetical bypass 
modeling for all transferred patients suggested that intravenous tissue plasminogen 
activator would be delayed by 12 minutes, but MT would be performed 91 minutes 
sooner if patients were routed directly to endovascular-capable centers. If bypass 
is limited to a 20-mile radius from onset, then intravenous tissue plasminogen 
activator would be delayed by 7 minutes and MT performed 94 minutes earlier.
CONCLUSIONS: In this large, real-world study, interhospital transfer was associated 
with significant treatment delays and lower chance of good outcome. Strategies 
to facilitate more rapid identification of large-vessel occlusion and direct routing to 
endovascular-capable centers for patients with severe stroke may improve outcomes.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique 
identifier: NCT02239640.
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Ischemic stroke is the leading cause of disability in the United States, and the burden of stroke continues to increase worldwide.1,2 Acute large-vessel occlusion 
(LVO) causes some of the largest and most disabling 
strokes.3 Fortunately, multiple recent trials have shown 
that endovascular mechanical thrombectomy (MT) leads 
to significantly better outcomes in patients with LVO 
stroke compared with medical therapy alone.4–8 STRATIS 
(Systematic Evaluation of Patients Treated With Neuro-
thrombectomy Devices for Acute Ischemic Stroke) was a 
prospective, multicenter, observational, single-arm reg-
istry of patients with LVO stroke treated with MT, which 
showed that outcomes similar to those observed in clini-
cal trials can be achieved in a real-world setting.9
The strongly positive effect of MT in acute stroke is 
highly time-dependent. A recent patient-level meta-
analysis of MT for LVO showed that the benefit associ-
ated with MT decreases with each 1-hour delay to treat-
ment, and that benefit became nonsignificant after 7.3 
hours from stroke onset.10 Thus, achieving timely treat-
ment is critically important to realize the benefits of MT. 
This timeliness is highly dependent on the entire system 
of care, including prehospital triage and routing. Many 
patients with acute stroke are transported to the near-
est hospital, which is often not capable of endovascular 
treatment. In these cases, patients undergo a rapid diag-
nostic workup, and may receive intravenous tissue-type 
plasminogen activator (IV-tPA) at the community hospi-
tal before being transferred to an endovascular-capable 
center. We hypothesized that such transfers might be 
associated with additional treatment delays and conse-
quent reduction in likelihood of good clinical outcome.
METHODS
Study Design and Inclusion Criteria
STRATIS was a prospective, multicenter, observational registry 
evaluating the use of Medtronic market-released MT devices 
in consecutive patients with acute ischemic stroke because 
of LVO in the anterior circulation between August 2014 and 
June 2016 from 55 sites (see Table I in the online-only Data 
Supplement for individual site characteristics) with approval 
from local institutional review boards. Patients were enrolled 
from the time of arrival at the enrolling hospital up to the 
day of hospital discharge, or ≤7 days after MT. Enrollment 
was planned to include ≤1000 patients to create the largest 
registry of patients with LVO stroke to date.
The inclusion criteria were (1) informed consent before 
enrollment in the registry, (2) acute stroke because of LVO 
that had been or would be treated with a Medtronic market-
released MT device as the initial device, (3) treatment within 
8 hours of stroke onset, (4) prestroke modified Rankin Scale 
(mRS) score of ≤2, and (5) pretreatment National Institutes of 
Health Stroke Scale (NIHSS) score of ≥8 and ≤30 as reported 
by the enrolling center. The qualifying NIHSS could be col-
lected at either the initial or enrolling hospital, and there 
was no requirement that it be repeated before MT. Use of 
a Medtronic MT device and enrollment in the registry were 
at the discretion of the site clinician-investigator; patients 
treated with other devices were not included in the registry.
Outcomes
The primary outcome was functional status as assessed by 
mRS at 90 days performed by the local treatment team, either 
in person or by telephone, and verification of assessor certi-
fication was not verified. Clinical end points were defined as 
follows: mRS 0 to 2 = functional independence, and mRS 0 to 
1 = excellent clinical outcome. Total stroke onset-to-revascu-
larization time was a secondary end point. Revascularization 
was defined as modified Thombolysis in Cerebral Ischemia 
2b or 3, corresponding to substantial or complete reperfu-
sion, and was determined by an independent core imaging 
laboratory. Only patients achieving successful revasculariza-
tion were included in time analyses. Patients were compared 
between 2 groups: those who presented directly to the 
endovascular-capable hospital (direct) versus patients who 
Clinical Perspective
What Is New?
• This large real-world study shows that patients 
who are transferred between hospitals for endo-
vascular stroke treatment have worse outcomes 
compared with those who presented directly to an 
endovascular-capable center.
• Delays to endovascular treatment account for the 
difference in outcomes between direct and transfer 
patients.
• A hypothetical bypass analysis showed that if 
patients were brought directly to the endovascular-
capable center, tissue plasminogen activator would 
be slightly delayed by 12 minutes, but endovascular 
treatment would be delivered 91 minutes sooner.
• If limited to bypass of <20 miles, tissue plasminogen 
activator is delayed by only 7 minutes, but endovas-
cular treatment is delivered 94 minutes sooner.
What Are the Clinical Implications?
• These findings reinforce that early recanalization 
leads to better outcomes. Stroke systems of care 
should be optimized to get patients to appropriate 
treatment quickly.
• When possible, interhospital transfer should be 
avoided.
• Our hypothetical bypass analysis showed that 
transporting patients directly to endovascular-
capable facilities has only a modest impact on tim-
ing of intravenous tissue plasminogen activator 
delivery but can have a significant reduction in time 
to endovascular recanalization.
• This finding was especially true for bypass distances 
of <20 miles.
• Thus, bypass to the nearest endovascular-capable 
stroke center should be strongly considered if it is 
within 20 miles.
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came by interhospital transfer to the endovascular-capable 
hospital (transfer) and were additionally categorized as hav-
ing received IV-tPA before MT or undergoing MT alone. The 
impacts of time to treatment, direct presentation versus 
transfer, and IV-tPA were assessed with a multivariate logistic 
regression accounting for other covariates. For analyses of 
outcome and time, the onset-to-puncture time epoch was 
used rather than time to revascularization so that all patients 
were included. Mortality rates at 90 days were also compared 
between direct and transfer groups. Early ischemic changes 
on the initial noncontrast head computed tomography were 
quantified using the ASPECTS score (Alberta Stroke Program 
Early CT Score), a validated measure of ischemic changes cor-
relating with clinical outcome.11 All imaging was evaluated 
by a core laboratory (University of California, Los Angeles 
Neurovascular Imaging Research Core).
Hypothetical Bypass Analysis
To reduce delays to MT, some have proposed direct emergency 
medical services routing to endovascular-capable centers.12–14 
To evaluate the potential impact of such a strategy, we per-
formed hypothetical bypass modeling for patients who had 
been brought by emergency medical services first to a nonen-
dovascular hospital and then transferred by ground ambulance 
to the endovascular-capable center (air transfer patients were 
excluded because the distances can be farther and ground 
velocity could not be predicted). The projected direct-to-endo-
vascular-capable hospital (bypass) time was calculated based 
on the actual driving distance from the scene directly to the 
endovascular-capable center combined with the actual aver-
age ambulance velocity observed during the interfacility trans-
port and a projected average emergency medical services time 
on scene of 15 minutes.15–17 For patients with IV-tPA, the aver-
age (mean) door–to–tissue-type plasminogen activator (tPA) 
time at endovascular-capable sites was then added to pre-
dict onset-to-tPA time. Any patients whose predicted bypass 
onset-to-tPA time exceeded guideline recommendations15 
were identified as no longer tPA-eligible. Finally, average door-
to-puncture time was added to yield total bypass-projected 
treatment time. This analysis was repeated for patients initially 
within 20 miles of the endovascular-capable center because 
nearer bypasses may be more plausible.
Statistical Analysis
Standard descriptive statistics were used, including mean, 
SD, and median with interquartile range (IQR) for continu-
ous variables and frequency distributions for categorical vari-
ables. For between-group comparisons, t tests and Wilcoxon’s 
rank sum were used for continuous variables, and χ2 tests 
and Fisher exact tests was used for categorical variables. Two-
tailed P values <0.05 were considered statistically significant. 
Statistical analyses were conducted in SAS version 9.2 or 
above (SAS Institute) and R version 3.2 or above (R Foundation 
for Statistical Computing). Outcome variables (mRS) were 
modeled against predictors of interest using logistic regres-
sion adjusted for age, qualifying NIHSS, occlusion location, 
use of tPA, transfer status, and time from onset. In this model, 
age, NIHSS, and time from onset were regarded as continu-
ous predictors, whereas occlusion location, tPA, and transfer 
status were categorical. Time from onset, as the continuous 
predictor of principal interest, was also evaluated using a 
quadratic term in the regression. Confidence intervals (CIs) 
for odds ratios (ORs) were derived from these models using 
normal approximation based on standard errors, whereas 
predicted probabilities from the same models are presented 
in graphical format. The distribution of mRS between groups 
was compared using the Mantel-Haenszel ordinal χ2 statistic.
Additionally, as a sensitivity analysis, propensity scores 
were constructed with transfer status as the object of pro-
pensity scoring and age, qualifying NIHSS, vessel of target 
occlusion, tPA administration, ASPECTS score at baseline, sex, 
arterial occlusion location, smoking status, history of atrial 
fibrillation, diabetes mellitus, history of recent stroke, carotid 
artery stenosis, history of coronary disease, hyperlipidemia, 
prestroke functional status, and hypertension as predictors. 
These covariates reflect all the variables analyzed in the recent 
randomized trials of endovascular treatment for stroke4–8 and 
the subsequent meta-analyses.18,19 The model for outcome 
(functional independence, mRS 0–2) was then constructed 
using transfer status, time from onset to arterial puncture, 
and propensity as predictors in 2 fashions: by using the pro-
pensity score as a covariate in the model, and by stratification 
into 5 groups based on propensity scores as per Rosenbaum 
and Rubin.20
RESULTS
A total of 1000 patients were enrolled over 22 months, 
but 16 did not meet the inclusion criteria (5 had baseline 
mRS>2, 4 were treated beyond 8 hours, 2 consented 
outside the enrollment window, 2 were without LVO, 1 
lacked documentation of consent, 1 had an NIHSS<8, 
and 1 had missing data), leaving 984 patients available 
for analysis. Direct presentation to the endovascular-
capable site was observed in 539 patients, and the 
remaining 445 were transferred from another hospi-
tal to the endovascular-capable hospital for treatment. 
Baseline characteristics were mostly similar between 
these 2 groups (Table 1), with predictable differences in 
mean initial NIHSS score (18.0±5.5 for transfers versus 
16.7±5.5 for direct; P=0.0006) and ASPECTS score by 
core laboratory assessment (7.9±1.8 for transfers versus 
8.4±1.4 for direct; P<0.0001). IV-tPA was administered 
to 628 patients: 329/539 (61.0%) of direct patients and 
299/445 (67.2%) of transferred patients (P=0.044).
Time Metrics
Median onset-to-revascularization time was 202.0 min-
utes (IQR, 160–265) in the direct group compared with 
311.5 minutes (IQR, 255–386) in the transfer group 
(P<0.001), with a difference between the mean times of 
100 minutes. The mean alarm-to-revascularization time, 
measuring system efficiency defined as time of 911 
call to treatment reperfusion, differed by 116 minutes. 
Among patients who received tPA, median onset-to-
revascularization time was 192.0 minutes (IQR, 156–239) 
for the direct group compared with 311.5 minutes (IQR, 
Froehler et al
December 12, 2017 Circulation. 2017;136:2311–2321. DOI: 10.1161/CIRCULATIONAHA.117.0289202314
257–381) for the transferred group (P<0.001). A com-
parison of mean times yields a difference of 124 minutes 
between the 2 groups, which was primarily related to 
longer door-to-tPA times at nonenrolling hospitals (me-
dian, 54.5 versus 37.0, P<0.001), delays between IV-tPA 
and departure from the initial hospital (median, 47 min-
utes; IQR, 27–85), and length of transport time (median, 
35 minutes; IQR, 21–58) (Figure 1A). Similarly among 
MT-alone patients, median onset-to-revascularization 
time was 229.0 minutes (IQR, 175–363) for the direct 
group compared with 311.5 minutes (IQR, 247–401) for 
the transferred group (P<0.001), which was primarily 
related to the delay between imaging completion and 
departure from the transferring hospital (median, 75 
minutes; IQR, 55–116) plus the length of transport time 
(median, 35 minutes; IQR, 23–50) (Figure 1B).
Clinical Outcomes
Clinical outcomes at 90 days were better in the direct 
group, with 60.0% (299/498) achieving functional inde-
pendence (mRS 0–2) compared with 52.2% (213/408) 
in the transfer group (unadjusted OR, 1.38; 95% CI, 
1.06–1.79; P=0.02) (Figure 2A). Likewise, excellent out-
Table 1. Baseline and Clinical Characteristics According to Admission Status
Characteristics All Transfer Direct P Value
Patients, no. 984 445 539  
Age, mean (SD), y 67.8 (14.7) 66.9 (14.6) 68.5 (14.8) 0.10
Male sex, no. (%) 533 (54.2) 245 (55.1) 288 (53.4) 0.61
Medical history, no. (%)
  Atrial flutter/atrial fibrillation 369 (37.5) 165 (37.1) 204 (37.8) 0.80
  Systemic hypertension 712 (72.4) 321 (72.1) 391 (72.5) 0.89
  Diabetes mellitus 252 (25.6) 108 (24.3) 144 (26.7) 0.38
  Myocardial disease/coronary artery disease 269 (27.3) 121 (27.2) 148 (27.5) 0.93
  Hyperlipidemia 414 (42.1) 184 (41.3) 230 (42.7) 0.68
  Peripheral artery disease 37 (3.8) 14 (3.1) 23 (4.3) 0.36
  Carotid artery disease 77 (7.8) 39 (8.8) 38 (7.1) 0.32
  Current or former tobacco use 465 (47.3) 222 (49.9) 243 (45.1) 0.13
Occlusion location
  ICA 223 (22.7) 100 (22.5) 123 (22.8) 0.31
  M1 541 (55.0) 250 (56.2) 291 (54.0)
 M2 172 (17.5) 69 (15.5) 103 (19.1)
  Other 48 (4.9) 26 (5.8) 22 (4.1)
Clinical characteristics
Prestroke mRS, no. (%)*    0.16
  0 748 (76.0) 326 (73.3) 422 (78.3)  
  1 209 (21.2) 104 (23.4) 105 (19.5)  
  2 27 (2.7) 15 (3.4) 12 (2.2)  
Initial qualifying NIHSS score, mean (SD), median (IQR)† 17.3 (5.5), 17.0 (13–22) 18.0 (5.5), 18.0 (13–22) 16.7 (5.5), 17.0 (12–21) <0.001
Treatment with IV-tPA, no. (%) 628 (63.8) 299 (67.2) 329 (61.0) 0.044
Baseline ASPECTS—per imaging core laboratory‡§ N=763 N=306 N=457 <0.001
 Mean (SD), median (IQR) 8.2 (1.6), 8.0 (8–9) 7.9 (1.8), 8.0 (7–9) 8.4 (1.4), 9.0 (8–9)  
Successful reperfusion (mTICI 2b-3)—per imaging core 
laboratory‖
N=824 N=356 N=468
 
 No. (%) 724 (87.9) 312 (87.6) 412 (88.0) 0.91
ASPECTS indicates Alberta Stroke Program Early Computed Tomography Score; CT, computed tomography; ICA, internal carotid artery; IQR, interquartile 
range; IV-tPA, intravenous tissue plasminogen activator (alteplase); M1, first segment of middle cerebral artery; M2, second segment of middle cerebral 
artery; mRS, modified Rankin Scale; mTICI 2b-3, modified treatment in cerebral ischemia; NIHSS, National Institutes of Health Stroke Scale.
*The mRS ranges from 0 to 6, with higher scores indicating greater degree of disability.
†NIHSS ranges from 0 to 42, with higher scores indicating more severe neurological deficits.
‡ASPECTS ranges from 0 to 10, with higher scores indicating a smaller infarct core.
§Baseline imaging received for 835 patients, of whom 72 were not evaluated for ASPECTS (38 posterior stroke, 30 no noncontract CT, 4 not evaluable); 
763 patients were evaluable for ASPECTS.
‖Angiograms received for 846 patients, of whom 22 were not evaluable for reperfusion status.
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come of mRS 0 or 1 was achieved in 47.4% (236/498) 
of direct patients versus 38.0% (155/408) of trans-
fer patients (OR, 1.47; 95% CI, 1.13–1.92; P=0.005). 
Comparing overall outcome by mRS shift analysis also 
favored direct presentation (P=0.012 by Cochran-Man-
tel-Haenszel test). Mortality did not differ between the 2 
groups (15.0% for direct, 13.7% for transfer; P=0.56).
Among patients who received IV-tPA before MT, 
outcomes at 90 days were better in the direct group, 
with 62.1% (190/306) achieving mRS 0 to 2 compared 
with 53.5% (146/273) in the transfer group (OR, 1.42; 
95% CI, 1.02–1.98; P=0.036) (Figure  2B). Excellent 
outcomes (mRS 0–1) for patients who received IV-tPA 
before MT were also observed more frequently in the 
direct group compared with the transfer group (48.7% 
versus 39.9%; OR, 1.43; 95% CI, 1.03–1.99; P=0.04). 
In the MT-alone group, functional independence was 
more common in the direct group (56.8%; 109/192) 
versus the transfer group (50.0%; 67/134), although 
this difference was not statistically significant (P=0.23) 
(Figure  2B). For MT alone, excellent outcomes (mRS 
0–1) were also observed more frequently in the direct 
group compared with the transfer group (45.3% ver-
sus 34.3%; OR, 1.59; 95% CI, 1.00–2.50; P=0.047). 
Comparison of outcomes by mRS shift analysis revealed 
a significant difference between transfer and direct 
groups for MT alone (P=0.035) and a nonsignificant 
trend for IV-tPA (P=0.14).
To determine the effect on outcome attributable to 
delay in time to treatment, multivariate logistic regres-
Figure 1. Median time intervals 
from stroke onset (the time of 
last seen well) through revascu-
larization.  
A, All patients who received IV-tPA 
before MT. There is a significant dif-
ference in onset-to-revascularization 
times (blue line). B, All patients who 
underwent MT alone (no IV-tPA). 
There is a significant difference in 
onset-to-revascularization times (blue 
line). EMS indicates emergency medi-
cal services; IV-tPA, intravenous tissue 
plasminogen activator; and MT, 
mechanical thrombectomy.
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sion was used with the outcome of functional indepen-
dence (mRS 0–2) by time from onset while accounting 
for multiple covariates (Table  2). Good outcome was 
less likely with increasing age, increasing NIHSS before 
treatment, and intracranial internal carotid artery oc-
clusion (versus middle cerebral artery). Increasing time 
from onset to treatment was also significantly associ-
ated with lower likelihood of good outcome, with an 
adjusted OR of 0.93 for every additional 30-minute de-
lay (95% CI, 0.89–0.98; P=0.008). When time to treat-
ment was accounted for, there was no additional effect 
of direct presentation versus transfer on functional out-
come (adjusted OR, 1.05; 95% CI, 0.76–1.45). Figure 3 
displays the effect of time to treatment on outcome 
for both direct and transfer patients. Although time to 
treatment is systematically longer in the transfer group, 
the effect of time on outcome as measured by the slopes 
of the 2 response curves is similar (P=0.35, test of in-
teraction effect between transfer status and time), sup-
porting the hypothesis that the difference between the 
2 groups is solely because of treatment delay. Across all 
patients, the absolute rate of functional independence 
decreased by 5.5% per hour from alarm to puncture. 
Additional univariate analysis showed that successful 
reperfusion was also strongly correlated with functional 
independence (OR, 2.21; 95% CI, 1.42–3.43).
We performed an additional propensity score anal-
ysis to assess the role of all available standard stroke 
covariates, including age, qualifying NIHSS, vessel of 
target occlusion, tPA administration, ASPECTS score at 
baseline, sex, arterial occlusion location, smoking sta-
tus, history of atrial fibrillation, diabetes mellitus, his-
tory of recent stroke, carotid artery stenosis, history of 
coronary disease, hyperlipidemia, prestroke functional 
status, and hypertension. After further adjustment 
for these variables and as seen in the multivariate re-
gression analysis, results after propensity adjustment 
indicated a significant effect of time but not transfer 
status, as shown in Table 3. Also as before, the interac-
tion between tPA and time was nonsignificant in the 
propensity-adjusted models, with P=0.14 for the co-
variate model and P=0.15 for the stratified model.
Hypothetical Bypass Analysis
A total of 209 patients were transferred via ground 
and available for analysis in the hypothetical bypass 
scenario. Of these patients, 122 (58.4%) received IV-
tPA at the first hospital, with a median onset-to-tPA 
time of 106 minutes (IQR, 81–136). Using the bypass 
model, 116 (95.1%) would still receive IV-tPA (6 no lon-
ger met guideline recommendations), and the median 
Figure 2. Unadjusted clinical outcomes at 90 days 
based on mRS, presented as percentage of the total.  
A, All patients, divided by direct admission (top) vs. inter-
hospital transfer (bottom). There is a significant difference 
between the 2 groups by shift analysis (P=0.012 by Cochran-
Mantel-Haenszel test). B, Comparison of outcomes based on 
mRS between direct and transfer divided into patients who 
received IV-tPA before MT (top) and those who underwent 
MT alone (bottom). Shift analysis revealed a significant 
difference between transfer and direct groups for MT alone 
(P=0.035) and a nonsignificant trend for IV-tPA (P=0.14). IV-
tPA indicates intravenous tissue plasminogen activator; mRS, 
modified Rankin Scale; and MT, mechanical thrombectomy.
Table 2. Effect on Good Functional Outcome 
Attributable to Delay in Time to Treatment
Predictor
Effect on Functional 
Independence:
Odds Ratio (95% CI) P Value
Age (per 10 y) 0.78 (0.71–0.87) <0.001
Qualifying NIHSS (per 5 points) 0.66 (0.58–0.76) <0.001
Location of intracranial target occlusion
 Internal carotid artery 0.57 (0.41–0.81) 0.002
  Middle cerebral artery–second 
segment (M2)
0.86 (0.58–1.27) 0.455
  Middle cerebral artery–first 
segment (M1) (reference)
1.00 (NA) NA
IV-tPA delivered (vs. mechanical 
thrombectomy alone)
1.04 (0.77–1.41) 0.809
Direct admit (vs. transfer) 1.05 (0.76–1.45) 0.767
Time: onset to puncture  
(per 30 min)
0.93 (0.89–0.98) 0.008
CI indicates confidence interval; IV-tPA, intravenous tissue plasminogen 
activator (alteplase); NA, not applicable; and NIHSS, National Institutes of 
Health Stroke Scale.
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onset-to-tPA time would increase to 123 minutes (IQR, 
90–160). The median onset-to-puncture time in all 
209 patients was 250 minutes (IQR, 201–330), which 
would decrease to 169 minutes (IQR, 133–223) with 
hypothetical bypass. When comparing mean times, 
tPA would be administered 12.0 minutes later (±SD of 
46.9), but endovascular treatment would be delivered 
91.0 minutes sooner (±47.6).
A total of 130 patients were transferred despite ini-
tially being within 20 miles of the endovascular hospital. 
Among these patients, 71 (54.6%) received IV-tPA at the 
first hospital, with a median onset-to-tPA of 100 min-
utes (IQR, 80–130). In the hypothetical bypass model, 69 
(97.2%) would still receive IV-tPA (2 excluded by guide-
lines), and median onset-to-tPA would increase to 102 
minutes (IQR, 78–143). Median onset-to-puncture in all 
130 patients was 240 minutes (IQR, 190–310), which 
would decrease to 148 minutes (IQR, 117–198) with hy-
pothetical bypass. When comparing mean times for the 
patients within 20 miles, tPA would be administered 6.9 
minutes later (±SD of 44.8), but endovascular treatment 
would be delivered 94.0 minutes sooner (±46.4).
DISCUSSION
This study provides important information regarding the 
impact of systems of care for patients with LVO stroke 
undergoing MT. We found that interhospital transfer was 
associated with mean treatment delays of 116 minutes 
compared with direct presentation to the endovascular-
capable center. Interhospital transfer was associated 
with lower chances of excellent clinical outcome (47.4% 
versus 38.0%) and lower chances of functional indepen-
dence (60.0% versus 52.2%). The difference in rates of 
good outcome between the 2 groups was entirely at-
tributable to time delays; when controlling for time from 
onset to treatment, there was no difference in outcomes 
between direct and transfer patients.
Time delays in the transfer group were mainly at-
tributable to 3 epochs: picture to departure for MT 
alone (75 minutes), tPA to departure for tPA+MT (47 
minutes), and transfer transport time (35 minutes). The 
first 2 time epochs suggest that much of the delay as-
sociated with transfer is because of medical decision 
making or the logistics of arranging transport. Despite 
these delays, other time epochs were actually shorter in 
the transfer group (such as picture-to-puncture times at 
Figure 3. Relationship between rate of functional independence (mRS 0–2 at 90 days) and time from onset to punc-
ture for direct (blue) vs. transfer (red) patients.  
The logistic curves have been truncated at the 95% distribution for each group, and thus the transfer group is shifted to the 
right (later average treatment time) compared with the direct group. Shading represents the 95% confidence interval for each 
group. The slopes do not differ between the 2 groups (P=0.35), suggesting that differences in outcome are related only to 
time. The rate of functional independence decreased by 5.5% per hour for all patients. mRS indicates modified Rankin Scale.
Table 3. Predictors of mRS 0 to 2 at 90 Days Using 
Propensity Score Analysis
Predictor of mRS 0–2
Model 1: Propensity 
Score as Covariate
Model 2: Propensity 
Score as Stratifier
Onset to arterial puncture 0.017 0.013
Transfer vs. direct 0.918 0.964
mRS indicates modified Rankin Scale.
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the enrolling hospital), presumably because of advance 
notice of the patient’s admission.
The relationship between time to treatment and out-
comes has been described in several recent studies. The 
recent HERMES analysis (Highly Effective Reperfusion 
Evaluated in Multiple Endovascular Stroke Trials) reported 
a linear reduction in chances of good outcome with in-
creasing time between onset and MT, with no significant 
benefit beyond 7.3 hours.10 A subanalysis of the SWIFT 
PRIME study (Solitaire FR With the Intention for Throm-
bectomy as Primary Endovascular Treatment for Acute 
Ischemic Stroke) found a high rate of good outcomes for 
patients treated with MT within 2.5 hours of onset, but 
this rate decreased by 10% over the next hour and by 
20% with every subsequent hour of delay.21 In the cur-
rent study, we found that the rate of good outcome was 
reduced by 5.5% for each 1-hour delay from alarm to 
puncture. The difference between these 2 studies likely 
reflects selection bias: patients enrolled in the random-
ized study were selected by a strict set of inclusion criteria, 
whereas patients in this real-world registry were treated 
based on the opinion of the local treatment team. These 
treatment decisions were likely based on various factors 
predictive of outcome, and patients likely to have a good 
outcome despite longer time from onset were probably 
still treated. Furthermore, the accelerated reduction in 
chance of good outcome after 3.5 hours that was seen 
in SWIFT PRIME21 was not observed in the current study. 
This difference is also likely attributable to enrollment dif-
ferences: patients who may have otherwise been eligible 
for MT but had imaging signs of established infarction 
were likely not treated as they were in SWIFT PRIME.
It is interesting to note that another recent but smaller 
registry of MT did not find a significant difference in out-
come between direct and transfer patients, despite on-
set-to-recanalization times of 297 versus 240 minutes.22 
However, that study was smaller (159 patients), included 
only a single referring center and a single MT center, and 
observed a smaller time difference between direct and 
transfer patients. Given that we observed a 5.5% reduc-
tion in good outcomes for each hour of delay, the results 
of this smaller study are not necessarily incongruent and 
may reflect circumstances specific to that singular cen-
ter. Another recent study using a large national database 
reported a higher mortality rate associated with transfer 
(18.6%) compared with direct presentation (14.9%) for 
MT.23 Although our study did not reveal a mortality differ-
ence between the 2 groups, the overall mortality rates are 
similar between the 2 studies. Given that the database 
study included 8533 patients, it is certainly reasonable to 
think that a small but significant mortality difference does 
exist between direct and transfer patient cohorts.
The administration of IV-tPA did not have a signifi-
cant impact on outcome in this cohort, and time to MT 
remained the most important determinant of outcome. 
However, it is important to note that any patient who 
successfully achieved thrombolysis with IV-tPA alone 
would not undergo MT and would become ineligible 
for the current registry. The impact of IV-tPA before 
MT was recently explored in a pooled analysis of the 
SWIFT and STAR studies (Solitaire FR With the Inten-
tion for Thrombectomy and Solitaire FR Thrombectomy 
for Acute Revascularization).24 That study showed a 
nonsignificant difference in rates of good outcome be-
tween patients treated with IV-tPA plus MT versus MT 
alone (57.7% versus 47.7%; P=0.10). Again, patients 
who responded to tPA before MT would not have been 
included. The true benefit of early tPA administration 
for LVO before MT can be assessed only with a properly 
conducted controlled trial, which is now clearly needed.
Currently, IV-tPA is often cited as the reason for avoid-
ing longer transport to an endovascular-capable center, so 
that IV-tPA can be administered sooner at a nearer hos-
pital.25–27 In the current study, analysis of all patients un-
dergoing interhospital transfer by ground ambulance sug-
gested that a direct-to-endovascular bypass would delay 
IV-tPA to a modest degree (12 minutes) and 5% would 
no longer be eligible for tPA, but the start of endovascular 
therapy would be greatly accelerated (91 minutes sooner). 
When limiting the hypothetical model only to patients ini-
tially within 20 miles of the endovascular center, bypass 
becomes even more appealing: tPA is delayed by only 6.9 
minutes, only 3% miss the opportunity for tPA, and endo-
vascular treatment starts 94 minutes sooner.
A significant delay to treatment because of interhospi-
tal transfer may also create a missed opportunity for MT. 
Although such patients would not be captured by the 
current registry, Sablot et al28 recently described a series 
of LVO patients transferred for MT after receiving IV-tPA 
at a nonendovascular center. Of 119 patients transferred, 
only 52 (44%) actually underwent MT. Significant treat-
ment delays associated with interhospital transfer were 
identified as the primary reason that MT was withheld. 
Thus, although bypassing the closer hospital may create 
missed opportunities for IV-tPA, interhospital transfer ap-
pears to create significant missed opportunities for MT.
As systems of care change to accommodate and op-
timize acute stroke treatments, the triage and transport 
of patients with acute stroke suspected of having LVO 
may have a significant impact on the emergency de-
partment resources. Currently available clinical scales 
for use in the field have high rates of false-positive re-
sults, with <50% of suspected patients actually under-
going MT.29 Such an influx of unnecessary emergency 
department admissions may create a significant burden 
on treatment teams. Clearly, more accurate means of 
rapid triage and diagnosis are needed.
In the interest of accelerating time to treatment with 
both IV-tPA and MT, one might consider offering endo-
vascular therapy at more hospitals (ie, those that are not 
currently endovascular-capable). In fact, a majority of des-
ignated Primary Stroke Centers  already offer some form 
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of endovascular treatment, despite not being designated 
as Comprehensive Stroke Centers.30 Conceptually, decen-
tralizing the availability of neurointerventionalists would 
improve treatment times. However, others have shown 
that mortality after stroke intervention is clearly depen-
dent on volume: 1 study reported mortality of 19.7% 
at low-volume, 14.9% at medium-volume, and 9.8% 
at high-volume centers (P=0.003).31  Although it is un-
clear whether these mortality differences are related to 
the procedure or perioperative care, some have argued 
for transportation of the neurointerventionalist to the pa-
tient, rather than the other way around. Hui et al32 report-
ed a single case of LVO stroke where the neurointerven-
tionalist was flown to a nonendovascular Primary Stroke 
Center and carried out MT there. Patient outcome and 
disposition were not reported, but the case does provide 
proof of concept and may justify further investigation.
This study does have several limitations. Some dif-
ferences between the direct and transfer groups were 
observed. Specifically, transferred patients had higher 
initial NIHSS, suggesting patients with more severe 
strokes were transferred for MT. Aside from stroke se-
verity as assessed by the NIHSS, other selection biases 
may have led to greater differences between the groups 
that could not be accounted for with regression analy-
sis. In fact, additional confounders, such as time of day 
or insurance status, are unknown and unaccounted for 
in the current study. Furthermore, transferred patients 
were more often treated with tPA, which may be re-
lated to earlier presentation at the community hospital. 
The ASPECTS on imaging before MT was worse in the 
transfer group compared with the direct group, likely a 
product of longer delays to treatment in the transferred 
patients. Although these differences were accounted 
for by multivariate regression, they may still have an 
influence on the analysis. Another important limitation 
of this study is that patients who experienced successful 
recanalization with IV-tPA would be excluded. Finally, 
the hypothetical bypass analysis is potentially biased by 
unknown variables, such as situational traffic delays.
Conclusions
This large, real-world registry of MT for stroke because 
of LVO has shown that interhospital transfer before 
endovascular treatment with MT is associated with de-
lays to treatment and a significantly lower chance of 
good outcome compared with direct presentation to 
the endovascular-capable center. Strategies to facilitate 
more rapid identification of LVO and direct routing to 
endovascular-capable centers for patients with severe 
stroke may help improve outcomes.
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